Ali Behbahani sold $229k of ADAPY
director at Adaptimmune Therapeutics PLC. 19,500,000 shares at an average of $0.01, traded Aug 15, 2025, filed Aug 19, 2025.
Score components
- +15RoleDirector
- +13Trade size$229k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +158.1%, 3m -8.1%, 6m -51.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-110254, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 15, 2025 | SOpen-market sale Ordinary Shares with a nominal value of 0.001 GBP per shareindirect: See Note 3 | -4,828,206 | $0.01 | $53k | 14,671,794 | Aug 19, 2025 |
| Aug 18, 2025 | SOpen-market sale Ordinary Shares with a nominal value of 0.001 GBP per shareindirect: See Note 3 | -14,671,794 | $0.01 | $176k | 0 | Aug 19, 2025 |
Related signals
Other insiders at Adaptimmune Therapeutics PLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Adaptimmune Therapeutics PLC | Gavin Wood Chief Financial Officer | $950 96,000 shares | -100% | |
| 40Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $2,091 207,000 shares | -17% | |
| 47Moderate | ADAPYsell Adaptimmune Therapeutics PLC | EcoR1 Capital, LLC owner | $6.9M 64,052,538 shares | -39% | |
| 50Moderate | Adaptimmune Therapeutics PLC | Adrian Rawcliffe Chief Executive Officer | $18k 30,601 shares | -41% | |
| 45Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | Elliot Norry Chief Medical Officer | $3,243 5,584 shares | -43% | |
| 55Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $11k 19,542 shares | -193% | |
| 50Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $11k 19,542 shares | -193% | |
| 50Moderate | Adaptimmune Therapeutics PLC | Elliot Norry Chief Medical Officer | $13k 22,195 shares | -219% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.